During a live event, Matthew Lunning, DO, discussed key factors that determine whether patients should receive CAR T-cell ...

Kyverna Therapeutics stock upgraded to Strong Buy after positive phase 2 results for miv-cel in SPS and MG. Read the latest ...

T cell immunotherapies are on the cutting-edge of cancer treatments, but a full understanding of how they work has been ...

Ryan Notti (left) and Thomas Walz (right) discovered new characteristics of a T cell receptor that are essential to a variety ...

Stem cells elicit immunomodulatory properties through surface protein expression and their secretome. These properties allow stem cells to influence the ...

Vyriad, Inc., a clinical-stage biotechnology company developing targeted genetic therapies for cancer and other serious diseases, presented detailed data on its lentiviral vector retargeting ...

Scientists showed that using new molecules that block an immune "checkpoint" could stimulate a "strong" anti-tumor immune ...

One of the most exciting advances in cancer treatments in the past decade is the development of T cell immunotherapies, in which a patient's own immune system is trained to recognize and attack ...

Researchers at MIT and Stanford University have developed a new way to stimulate the immune system to attack tumor cells, using a strategy that could make cancer immunotherapy work for many more ...

A hidden “jack-in-the-box” mechanism inside T cells may hold the key to unlocking more powerful cancer immunotherapies.

Arbitration Ruling Reaffirms Allogene’s Full Control of Cemacabtagene Ansegedleucel (Cema-Cel)Decision Reconfirms Allogene’s ...

Summary • Pfizer’s stock is up 1.8% to $26.305 during intraday trading, driven by recent collaborative agreements.• Agreements with Adaptive Biotechnologies focus on T-cell receptor discovery and data ...